Épingles correspondant à place:Cambridge

Alan Turing submits "On Computable Numbers, with an Application to the Entscheidungsproblem" to the London Mathematical Society. It defines the abstract machine that became the model for every computer built since, and proves the Entscheidungsproblem undecidable.

Nature carries Molecular Structure of Nucleic Acids: A Structure for Deoxyribose Nucleic Acid, the paper in which Francis Crick and James Watson describe the double helix. It runs to two pages and settles how genetic instructions are held and passed on.

Georges Köhler and César Milstein report in Nature that fusing an antibody-producing cell with a myeloma cell yields a line that secretes a single antibody indefinitely. Monoclonal antibodies become the basis of the modern biologics industry.

AstraZeneca's phase 3 trial of Camizestrant in breast cancer, early breast cancer reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,300 participants. This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The planned duration of treatment in either arm of the study is 60 months.

AstraZeneca's phase 3 trial of Tozorakimab in viral lung infection and acute respiratory failure reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 3,527 participants. The purpose of this study is to evaluate the effect of tozorakimab, as an add-on to SoC in patients with viral lung infection requiring supplemental oxygen, on the prevention of death or progression to IMV/ECMO.

AstraZeneca's phase 3 trial of BGF MDI 320/14.4/9.6 μG in copd reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,000 participants. This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.

Kalshi’s recession market for 2027 prices the chance of two consecutive quarters of negative GDP growth between Q4 2026 and Q4 2027, on the Bureau of Economic Analysis’s advance estimates — despite the KXRECSSNBER ticker, no NBER call is involved. On 20 September 2026 it sat at 25%, its 2026 contract at 6%, and Polymarket’s cumulative "recession by end of 2027" book, which also counts an NBER announcement, was higher still at 34.5%.

The first of two connected towers in Mass General's Cambridge Street expansion takes its first patients, bringing 450 beds and 12 levels of operating, procedural and interventional space for the Corrigan Minehan Heart Center and the Mass General Cancer Center. Turner topped out the steel in February 2025; the second tower is not due until 2030.

AstraZeneca's phase 3 trial of Elecoglipron in type 2 diabetes mellitus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.

AstraZeneca's phase 3 trial of Elecoglipron in weight management reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 4,500 participants. This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).

AstraZeneca's phase 3 trial of AZD6234 in obesity or overweight reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,500 participants. The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment